{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:12:09Z","timestamp":1790349129512,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"STI2030-Major Projects","award":["2022ZD0213800"],"award-info":[{"award-number":["2022ZD0213800"]}]},{"name":"the National Science Foundation of China","award":["81801752, 82171473, 82201583, and 82071962"],"award-info":[{"award-number":["81801752, 82171473, 82201583, and 82071962"]}]},{"name":"the startup fund of Huashan Hospital, Fudan University","award":["2017QD081"],"award-info":[{"award-number":["2017QD081"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Various plasma phosphorylated tau species have been shown to be associated with amyloid-\u03b2 (A\u03b2) PET and Tau PET in Alzheimer\u2019s disease (AD), but whether APOE \u03b54 affects the interaction between glial fibrillary acidic protein (GFAP) and phosphorylated tau (pTau), and whether a three-way interaction exists among APOE \u03b54, GFAP, and pTau that influences AD progression remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included 563 participants from the Chinese Preclinical Alzheimer\u2019s Disease Study (CPAS) and 243 from Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI), all of whom underwent A\u03b2 PET, magnetic resonance imaging (MRI), neuropsychological assessments, and plasma biomarker analyses (GFAP, pTau181, pTau231, pTau217), with subsets undergoing Tau PET. The longitudinal data of 101 participants from ADNI were additionally included. We employed linear regression models with interaction terms to examine how APOE \u03b54 status and plasma GFAP levels modulate the relationships between plasma pTau biomarkers and AD pathology cross-sectionally and longitudinally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Plasma GFAP and pTau biomarkers (pTau181, pTau231, pTau217) are significantly elevated in A\u03b2-positive individuals, with stronger A\u03b2\u2013pTau associations observed in APOE \u03b54 carriers (CPAS: \u03b2\u2009=\u20090.26,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003 for pTau231; ADNI: \u03b2\u2009=\u20090.45,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 for pTau181). Across two cohorts, plasma GFAP levels significantly strengthened the associations between pTau biomarkers and Tau PET. Furthermore, subsequent analyses revealed that this modulatory effect of GFAP on the links between pTau and PET-derived pathological changes was more pronounced in APOE \u03b54 non-carriers, whereas in APOE \u03b54 carriers, a significant interaction between GFAP and pTau was only observed in specific Braak stage-specific regions within the CPAS cohort. In longitudinal analyses, we also observed stronger pTau181-associated longitudinal tau accumulation in individuals with high GFAP levels (Braak III-IV).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We demonstrate that APOE \u03b54 status critically modulates the relationship between pTau and A\u03b2 pathology, whereas plasma GFAP primarily influences pTau\u2013tau pathology associations, particularly in individuals without APOE \u03b54 allele. These findings underscore the role of reactive astrogliosis in tau propagation and support the utility of plasma biomarkers for AD diagnosis and prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-025-00906-0","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:34:28Z","timestamp":1761744868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Interplay between astrocyte reactivity and APOE \u03b54 status is associated with accelerated pTau-related tau pathology in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Xiaoxie","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger N.","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2667-281X","authenticated-orcid":false,"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"906_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer\u2019s disease. Eur J Neurol. 2018;25:59\u201370.","journal-title":"Eur J Neurol"},{"key":"906_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1586\/14737175.2015.1023296","volume":"15","author":"H Barthel","year":"2015","unstructured":"Barthel H, Seibyl J, Sabri O. The role of positron emission tomography imaging in Understanding alzheimer\u2019s disease. Expert Rev Neurother. 2015;15:395\u2013406.","journal-title":"Expert Rev Neurother"},{"key":"906_CR3","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1007\/s10571-023-01365-1","volume":"43","author":"YY Sun","year":"2023","unstructured":"Sun YY, Wang Z, Huang HC. Roles of ApoE4 on the pathogenesis in alzheimer\u2019s disease and the potential therapeutic approaches. Cell Mol Neurobiol. 2023;43:3115\u201336.","journal-title":"Cell Mol Neurobiol"},{"key":"906_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13195-020-00710-6","volume":"12","author":"MS Baek","year":"2020","unstructured":"Baek MS, Cho H, Lee HS, Lee JH, Ryu YH, Lyoo CH. Effect of APOE \u03b54 genotype on amyloid-\u03b2 and Tau accumulation in alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:140.","journal-title":"Alzheimers Res Ther"},{"key":"906_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-023-01209-6","volume":"15","author":"A Snellman","year":"2023","unstructured":"Snellman A, Ekblad LL, Tuisku J, Koivum\u00e4ki M, Ashton NJ, Lantero-Rodriguez J, et al. APOE \u03b54 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly. Alzheimers Res Ther. 2023;15:71.","journal-title":"Alzheimers Res Ther"},{"key":"906_CR6","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","volume":"12","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Janelidze S, Palmqvist S, Svenningsson AL, Stomrud E, et al. Plasma biomarkers of alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021;12:3555.","journal-title":"Nat Commun"},{"key":"906_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28:595\u20139.","journal-title":"Nat Biotechnol"},{"key":"906_CR8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius \u00c5, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016;54:1655\u201361.","journal-title":"Clin Chem Lab Med"},{"key":"906_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13024-023-00605-8","volume":"18","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Plasma phospho-tau in alzheimer\u2019s disease: towards diagnostic and therapeutic trial applications. Mol Neurodegener. 2023;18:18.","journal-title":"Mol Neurodegener"},{"key":"906_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for alzheimer disease pathology. JAMA Neurol. 2024;81:255\u201363.","journal-title":"JAMA Neurol"},{"key":"906_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.14283\/jpad.2023.43","volume":"10","author":"L Iaccarino","year":"2023","unstructured":"Iaccarino L, Burnham SC, Dell\u2019Agnello G, Dowsett SA, Epelbaum S. Diagnostic biomarkers of amyloid and Tau pathology in alzheimer\u2019s disease: an overview of tests for clinical practice in the united States and Europe. J Prev Alzheimers Dis. 2023;10:426\u201342.","journal-title":"J Prev Alzheimers Dis"},{"key":"906_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141:709\u201324.","journal-title":"Acta Neuropathol"},{"key":"906_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to alzheimer\u2019s dementia. Nat Med. 2020;26:379\u201386.","journal-title":"Nat Med"},{"key":"906_CR14","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not Tau pathology in alzheimer\u2019s disease. Brain. 2021;144:3505\u201316.","journal-title":"Brain"},{"key":"906_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13024-024-00750-8","volume":"19","author":"T Guo","year":"2024","unstructured":"Guo T, Li A, Sun P, He Z, Cai Y, Lan G, et al. Astrocyte reactivity is associated with Tau tangle load and cortical thinning in alzheimer\u2019s disease. Mol Neurodegener. 2024;19:58.","journal-title":"Mol Neurodegener"},{"key":"906_CR16","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s43587-023-00490-2","volume":"3","author":"JP Ferrari-Souza","year":"2023","unstructured":"Ferrari-Souza JP, Bellaver B, Ferreira PCL, Benedet AL, Povala G, Lussier FZ, et al. APOE\u03b54 potentiates amyloid \u03b2 effects on longitudinal Tau pathology. Nat Aging. 2023;3:1210\u20138.","journal-title":"Nat Aging"},{"key":"906_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00401-024-02744-8","volume":"147","author":"M Thierry","year":"2024","unstructured":"Thierry M, Ponce J, Mart\u00e0-Ariza M, Askenazi M, Faustin A, Leitner D, et al. The influence of APOE(\u03b54) on the pTau interactome in sporadic alzheimer\u2019s disease. Acta Neuropathol. 2024;147:91.","journal-title":"Acta Neuropathol"},{"key":"906_CR18","doi-asserted-by":"crossref","unstructured":"Wang C, Xiong M, Gratuze M, Bao X, Shi Y, Andhey PS, et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron. 2021;109:1657-74.e7.","DOI":"10.1016\/j.neuron.2021.03.024"},{"key":"906_CR19","doi-asserted-by":"publisher","first-page":"106175","DOI":"10.1016\/j.nbd.2023.106175","volume":"183","author":"A Snellman","year":"2023","unstructured":"Snellman A, Ekblad LL, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Pietil\u00e4 E, et al. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for alzheimer\u2019s disease. Neurobiol Dis. 2023;183:106175.","journal-title":"Neurobiol Dis"},{"key":"906_CR20","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1148\/rg.2018180160","volume":"38","author":"TF Lundeen","year":"2018","unstructured":"Lundeen TF, Seibyl JP, Covington MF, Eshghi N, Kuo PH. Signs and artifacts in amyloid PET. Radiographics. 2018;38:2123\u201333.","journal-title":"Radiographics"},{"key":"906_CR21","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2967\/jnumed.116.174615","volume":"57","author":"S Minoshima","year":"2016","unstructured":"Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, et al. SNMMI procedure Standard\/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med. 2016;57:1316\u201322.","journal-title":"J Nucl Med"},{"key":"906_CR22","doi-asserted-by":"crossref","unstructured":"Wang J, Huang Q, Chen X, You Z, He K, Guo Q, et al. Tau pathology is associated with synaptic density and longitudinal synaptic loss in alzheimer\u2019s disease. Mol Psychiatry. 2024;29:2799-809.","DOI":"10.1038\/s41380-024-02501-z"},{"key":"906_CR23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.biopsych.2020.06.029","volume":"89","author":"T Guo","year":"2021","unstructured":"Guo T, Korman D, Baker SL, Landau SM, Jagust WJ. Alzheimer\u2019s disease neuroimaging I. Longitudinal cognitive and biomarker measurements support a unidirectional pathway in alzheimer\u2019s disease pathophysiology. Biol Psychiatry. 2021;89:786\u201394.","journal-title":"Biol Psychiatry"},{"key":"906_CR24","doi-asserted-by":"crossref","unstructured":"Chen T, Pan F, Huang Q, Xie G, Chao X, Wu L, et al. Metabolic phenotyping reveals an emerging role of ammonia abnormality in alzheimer\u2019s disease. Nat Commun. 2024;15:3796.","DOI":"10.1038\/s41467-024-47897-y"},{"key":"906_CR25","doi-asserted-by":"crossref","unstructured":"He K, Li B, Huang L, Zhao J, Hua F, Wang T, et al. Positive rate and quantification of amyloid pathology with [(18)F]florbetapir in the urban Chinese population. Eur Radiol. 2023;34:3331-41.","DOI":"10.1007\/s00330-023-10366-z"},{"key":"906_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:263\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"key":"906_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2174\/1567205017666200807193253","volume":"17","author":"L Huang","year":"2020","unstructured":"Huang L, Chen K, Liu Z, Guo Q. A conceptual framework for research on cognitive impairment with no dementia in memory clinic. Curr Alzheimer Res. 2020;17:517\u201325.","journal-title":"Curr Alzheimer Res"},{"key":"906_CR28","volume-title":"Development and validation of Language and visuospatial composite scores in ADNI","author":"SE Choi","year":"2020","unstructured":"Choi SE, Mukherjee S, Gibbons LE, Sanders RE, Jones RN, Tommet D, et al. Development and validation of Language and visuospatial composite scores in ADNI. Volume 6. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions; 2020;6:e12072."},{"key":"906_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"906_CR30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2016.10.006","volume":"13","author":"MW Weiner","year":"2017","unstructured":"Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The alzheimer\u2019s disease neuroimaging initiative 3: continued innovation for clinical trial improvement. Alzheimers Dement. 2017;13:561\u201371.","journal-title":"Alzheimers Dement"},{"key":"906_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM, et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther. 2021;13:198.","journal-title":"Alzheimers Res Ther"},{"key":"906_CR32","doi-asserted-by":"publisher","first-page":"106356","DOI":"10.1016\/j.nbd.2023.106356","volume":"189","author":"AL Wojda\u0142a","year":"2023","unstructured":"Wojda\u0142a AL, Bellomo G, Gaetani L, Toja A, Chipi E, Shan D, et al. Trajectories of CSF and plasma biomarkers across alzheimer\u2019s disease continuum: disease staging by NF-L, p-tau181, and GFAP. Neurobiol Dis. 2023;189:106356.","journal-title":"Neurobiol Dis"},{"key":"906_CR33","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1038\/s43587-025-00904-3","volume":"5","author":"G Lan","year":"2025","unstructured":"Lan G, Wang M, Gonzalez-Ortiz F, Zhang L, Li A, Li B, et al. Comprehensive evaluation of plasma Tau biomarkers for detecting and monitoring alzheimer\u2019s disease in a multicenter and multiethnic aging population. Nat Aging. 2025;5:1601\u201318.","journal-title":"Nat Aging"},{"key":"906_CR34","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1002\/alz.13775","volume":"20","author":"K He","year":"2024","unstructured":"He K, Li B, Wang J, Wang Y, You Z, Chen X, et al. APOE \u03b54 is associated with decreased synaptic density in cognitively impaired participants. Alzheimer\u2019s Dement. 2024;20:3157\u201366.","journal-title":"Alzheimer\u2019s Dement"},{"key":"906_CR35","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00406-019-01083-0","volume":"270","author":"Q Huang","year":"2020","unstructured":"Huang Q, Ren S, Jiang D, Guan Y, Xie F, Sun D, et al. Changes in brain glucose metabolism and connectivity in somatoform disorders: an (18)F-FDG PET study. Eur Arch Psychiatry Clin Neurosci. 2020;270:881\u201391.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"906_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neuroscience.2019.07.048","volume":"417","author":"J Su","year":"2019","unstructured":"Su J, Huang Q, Ren S, Xie F, Zhai Y, Guan Y, et al. Altered brain glucose metabolism assessed by (18)F-FDG PET imaging is associated with the cognitive impairment of CADASIL. Neuroscience. 2019;417:35\u201344.","journal-title":"Neuroscience"},{"key":"906_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.24711","volume":"80","author":"H Cho","year":"2016","unstructured":"Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of Tau and amyloid in the alzheimer disease spectrum. Ann Neurol. 2016;80:247\u201358.","journal-title":"Ann Neurol"},{"key":"906_CR38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma Phospho-tau217 for alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772\u201381.","journal-title":"JAMA"},{"key":"906_CR39","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1038\/s41467-024-46603-2","volume":"15","author":"WS Brum","year":"2024","unstructured":"Brum WS, Cullen NC, Therriault J, Janelidze S, Rahmouni N, Stevenson J, et al. A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings. Nat Commun. 2024;15:2311.","journal-title":"Nat Commun"},{"key":"906_CR40","doi-asserted-by":"publisher","first-page":"105405","DOI":"10.1016\/j.ebiom.2024.105405","volume":"109","author":"A Feizpour","year":"2024","unstructured":"Feizpour A, Doecke JD, Dor\u00e9 V, Krishnadas N, Huang K, Bourgeat P, et al. Detection and staging of alzheimer\u2019s disease by plasma pTau217 on a high throughput immunoassay platform. EBioMedicine. 2024;109:105405.","journal-title":"EBioMedicine"},{"key":"906_CR41","doi-asserted-by":"crossref","unstructured":"Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron. 2017;96:1024-32.e3.","DOI":"10.1016\/j.neuron.2017.11.013"},{"key":"906_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","volume":"581","author":"A Montagne","year":"2020","unstructured":"Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581:71\u20136.","journal-title":"Nature"},{"key":"906_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13024-022-00516-0","volume":"17","author":"TE Mahan","year":"2022","unstructured":"Mahan TE, Wang C, Bao X, Choudhury A, Ulrich JD, Holtzman DM. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces A\u03b2 accumulation and plaque-related pathology in a mouse model of amyloidosis. Mol Neurodegener. 2022;17:13.","journal-title":"Mol Neurodegener"},{"key":"906_CR44","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","volume":"27","author":"TA Pascoal","year":"2021","unstructured":"Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, et al. Microglial activation and Tau propagate jointly across Braak stages. Nat Med. 2021;27:1592\u20139.","journal-title":"Nat Med"},{"key":"906_CR45","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1038\/s41380-022-01716-2","volume":"27","author":"JP Ferrari-Souza","year":"2022","unstructured":"Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang YT, Leffa DT, et al. Astrocyte biomarker signatures of amyloid-\u03b2 and Tau pathologies in alzheimer\u2019s disease. Mol Psychiatry. 2022;27:4781\u20139.","journal-title":"Mol Psychiatry"},{"key":"906_CR46","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in alzheimer\u2019s disease. Lancet Neurol. 2015;14:388\u2013405.","journal-title":"Lancet Neurol"},{"key":"906_CR47","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, et al. A soluble phosphorylated Tau signature links Tau, amyloid and the evolution of stages of dominantly inherited alzheimer\u2019s disease. Nat Med. 2020;26:398\u2013407.","journal-title":"Nat Med"},{"key":"906_CR48","doi-asserted-by":"crossref","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med. 2020;217:e20200861.","DOI":"10.1084\/jem.20200861"},{"key":"906_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","volume":"12","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Bateman RJ, Hirtz C, Marin P, Becher F, Sato C, et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of alzheimer\u2019s disease and PET amyloid-positive patient identification. Alzheimers Res Ther. 2020;12:26.","journal-title":"Alzheimers Res Ther"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00906-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00906-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00906-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:50:26Z","timestamp":1781614226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13024-025-00906-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00906-0","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol adhered to ethical guidelines and was approved by the Institutional Review Boards of Huashan Hospital, Fudan University, and Ruijin Hospital. Written informed consent was obtained from all participants prior to their enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"R.O. has received research funding\/support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics, has given lectures in symposia sponsored by GE Healthcare, is an advisory board member for Asceneuron and a steering committee member for Biogen and Bristol Myers Squibb. All the aforementioned has been paid to these institutions. The authors report no disclosures relevant to the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}